Nevertheless, the pharmacological interest toward liver AQP9 is strong as this aquaglyceroporin has good potentials to be a novel molecular target for therapeutic intervention in NAFLD and NASH. Here, AQP9 is linked to metabolic dysfunction-associated steatohepatitis.